Compare Cassava Sciences Inc (FLNA) vs Target Corporation (TGT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Target Corporation — how do they compare? Cassava Sciences Inc trades at $1.1 (market cap $53.14M), while Target Corporation trades at $140.05 (market cap $62.81B). The key difference: Target Corporation is far larger — about 1182× Cassava Sciences Inc's market cap, and Target Corporation pays a 3.36% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | TGT | |
|---|---|---|
Market Cap | $53.14M | $62.81B |
Sector | Health | Consumer Cyclical |
52-Week High | $4.64 | $141.19 |
52-Week Low | $1.09 | $83.68 |
Enterprise Value | -$33.43M | $78.11B |
Dividend Yield | — | 3.36% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
Target (TGT) trades at $140.69, up 5.02% today, with strong technical momentum indicated by bullish moving averages. Recent earnings beats and a 3.24% net income margin highlight operational resilience, while a P/E of 18.27 and P/S of 0.59 suggest reasonable valuation. Positive news flow notes improving traffic trends from merchandising initiatives, supporting near-term optimism.
The outlook remains balanced with potential upside from execution on merchandising resets and consistent dividend payments, but risks include competitive pressures and margin volatility. Analyst consensus is mixed with a $137 price target slightly below current levels, indicating cautious optimism amid solid fundamentals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Target Corporation
With 1,926 stores (as of the end of fiscal 2021), Target is a leading American general merchandise retailer, offering a variety of products across several categories, including beauty and household essentials (26% of fiscal 2021 sales), food and beverage (19%), home furnishings and décor (19%), hardlines (18%), and apparel and accessories (17%). Most of Target's stores are large, averaging more than 125,000 square feet. The company has a significant e-commerce presence, deriving around 19% of sales from the channel (up from about 9% in fiscal 2019, before the pandemic). In addition to its namesake stores, Target owns Shipt, an online same-day delivery platform. After it exited Canada in 2015, virtually all of Target's revenue is generated from the United States.
Read more on TGT →
